MIT SCALE RESEARCH REPORT

The MIT Global Supply Chain and Logistics Excellence (SCALE) Network is an international alliance of leading-edge research and education centers, dedicated to the development and dissemination of global innovation in supply chain and logistics.

The Global SCALE Network allows faculty, researchers, students, and affiliated companies from all six centers around the world to pool their expertise and collaborate on projects that will create supply chain and logistics innovations with global applications.

This reprint is intended to communicate research results of innovative supply chain research completed by faculty, researchers, and students of the Global SCALE Network, thereby contributing to the greater public knowledge about supply chains.

For more information, contact
MIT Global SCALE Network

Postal Address:
Massachusetts Institute of Technology 77
Massachusetts Avenue, Cambridge, MA 02139 (USA)

Location:
Building E40, Room 267
1 Amherst St.

Access:
Telephone: +1 617-253-5320
Fax: +1 617-253-4560

Email: scale@mit.edu
Website: scale.mit.edu

Research Report: MISI-2016-2
Decision Framework for Localization of Pharmaceutical Manufacture with Applications to Malaysia and Indonesia
Mahesh B. Yedluri and Veronica
For full thesis version please contact:
Professor Shardul Phadnis
Director of Research
MISI
No. 2A, Persiaran Tebar Layar, Seksyen U8, Bukit Jelutong, Shah Alam,
40150 Selangor, Malaysia.
Phone: +6 03 7841 4845
Email: sphadnis@misi.edu.my
**Decision Framework for Localization of Pharmaceutical Manufacture with Applications to Malaysia and Indonesia**

By: Mahesh B. Yedluri and Veronica
Thesis Advisor: Dr. Sang Jo Kim

**Summary:** A pharmaceutical company, Global Pharma (fictitious name), has strong presence in the western markets of Europe and the US, where the major manufacturing base is also located. With the shift in growth from these developed markets to the emerging markets of Asia, Latin America, Eastern Europe and Middle East Africa, there is a resulting increase in transportation of goods and hence cost and carbon footprint. At the same time, the company has opportunities to reduce these costs because localizing manufacturing in emerging markets offers will reduce the transportation costs and the carbon footprint. However, it requires significant investment and long-term planning for a pharmaceutical company to determine the viability to localize its manufacture in emerging markets. Localization is establishing one or more of a company’s functions in a country. These functions include and not limited to, manufacturing, research and development, warehousing, and procurement. In this study, we develop a framework to assist a pharmaceutical company in the localization decision-making. In the framework, a comprehensive list of key external factors are obtained and analyzed for their impact on localization in a particular market. Those factors are also grouped into pertinent categories that are arranged into logical levels according to their importance and the degree of the company’s control over them. We apply the framework for the localization decisions in Malaysia and Indonesia and the application of this framework infers that the atmosphere in the two countries is positive for localization.

*Mahesh B. Yedluri* holds a Bachelor of Technology degree in Civil Engineering from Acharya Nagarjuna University in India and a Master of Science in Civil Engineering from California State University, Sacramento. Prior to the MSCM Program, he worked as a civil engineering consultant in the United States.

*Veronica* holds Bachelor of Economics in Air Transportation Management from Trisakti Institute of Transportation Management. Prior to the MSCM Program, she worked at DHL Global Forwarding.
The company, Global Pharma (fictitious name), is a global pharmaceutical products manufacturer with strong emphasis in commercial pharmaceutical products. The company has a strong presence in North America, Europe, and Japan and is establishing a strong presence in the emerging markets. Global Pharma performs extensive research to develop innovative pharmaceuticals to treat ailments for which there are few affordable treatment options. The company is also committed to provide access to affordable healthcare to the broader population. The purpose of this thesis is to develop a framework that will assist Global Pharma in localization decisions. Localization is a process in which a company sets up one or more of its functions in a country. These functions can be manufacturing, research and development, services, purchasing, etc.

**Driving Factors for Localization**

The factors that are driving a company to localize are presented below.

**Push Factors**
- Increased transporation to ship finished products to emerging markets
- Increased transportation to procure raw materials from emerging markets
- Increased carbon footprint

**Pull Factors**
- Growth in the emerging markets
- Affordable labor force
- Improving infrastructure
- Availability of skilled workforce
- Lower raw material costs

**Research Questions and Scope**

This thesis aims to answer the following research questions:

1. What are the key external factors that influence the localization decisions?
2. What is the framework that will assist Global Pharma in the localization decision-making?

After a framework that assists in localization decisions is developed, it will be applied to Malaysia and Indonesia.

**Literature Review**

Several external factors are identified and they are arranged into following categories:
Examples of key factors under each category are presented in the table below.

<table>
<thead>
<tr>
<th>Category</th>
<th>Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Government Policy</td>
<td>Tendering, Tax Incentives, Business Approval Process</td>
</tr>
<tr>
<td>Regulatory Affairs</td>
<td>Patent Protection, Quality Assurance and Quality Control Requirements, Regulatory Requirements</td>
</tr>
<tr>
<td>Technology and Trade Policy</td>
<td>Production Technology, Tracking Technology, Trade Policy</td>
</tr>
<tr>
<td>Demographics</td>
<td>Gross Domestic Product, Population Density, Peoples beliefs in Foreign vs. Local</td>
</tr>
<tr>
<td>Competitors</td>
<td>Existing Competitors, Competitors’ Market Share, Competitors’ Growth</td>
</tr>
<tr>
<td>Foreign Direct Investment</td>
<td>History of Foreign Direct Investment (FDI), atmosphere for FDI.</td>
</tr>
<tr>
<td>Longevity and Growth</td>
<td>Market Stability, Market Conditions, Market Trends</td>
</tr>
<tr>
<td>Supply Chain</td>
<td>Infrastructure, Reliable Supplier Network, Customer Expectations</td>
</tr>
</tbody>
</table>

Contributions of this thesis:

(1) A comprehensive list of key factors that influence the localization decisions for the pharmaceutical companies in emerging markets.

(2) Categorization of factors and prioritizing categories.

(3) Identifying the impact of the factors as positive, negative or unknown using literature.

(4) A decision framework that uses categories and impact to support localization decisions.

Research Method

<table>
<thead>
<tr>
<th>Collect Data</th>
<th>Mainly through Literature Review</th>
</tr>
</thead>
<tbody>
<tr>
<td>Categorize Factors</td>
<td>Into eight pertinent categories</td>
</tr>
<tr>
<td>Analyze Factors</td>
<td>Positive, Negative, or Unknown impact</td>
</tr>
<tr>
<td>Develop Framework</td>
<td>Using three levels based on importance of categories</td>
</tr>
<tr>
<td>Apply Framework</td>
<td>To Malaysia and Indonesia</td>
</tr>
</tbody>
</table>

Applications of Framework to Malaysia and Indonesia

The following table presents the applications of framework to Malaysia and Indonesia.

A positive impact is assigned when more than 55 percent of the factors have positive impact. An unknown impact is assigned when at least 25 percent of the factors have an unknown impact and at least 45 percent of the factors have positive impact or at least 35 percent of the factors have unknown impact and only 35 percent of factors have a negative impact. A negative impact is assigned if at least 45 percent of the factors have a negative impact.

<table>
<thead>
<tr>
<th>Category</th>
<th>Malaysia</th>
<th>Indonesia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Government Policy</td>
<td>P: 87% (of factors have positive impact)</td>
<td>P: 67%</td>
</tr>
<tr>
<td>Regulatory Affairs</td>
<td>U: 33%</td>
<td>U: 25%</td>
</tr>
<tr>
<td>Technology</td>
<td>U: 83%</td>
<td>U: 83%</td>
</tr>
<tr>
<td></td>
<td>Level 2</td>
<td>Level 3</td>
</tr>
<tr>
<td>------------------</td>
<td>---------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Demographics</td>
<td>U: 33%</td>
<td>U: 40%</td>
</tr>
<tr>
<td>Competitors</td>
<td>P: 57%</td>
<td>P: 57%</td>
</tr>
<tr>
<td>FDI</td>
<td>P: 100%</td>
<td>U: 50%</td>
</tr>
<tr>
<td>Longevity and Growth</td>
<td>P: 100%</td>
<td>P: 75%</td>
</tr>
<tr>
<td>Supply Chain</td>
<td>P: 80%</td>
<td>P: 60%</td>
</tr>
</tbody>
</table>

**Notes:** P – Positive, N – Negative, U - Unknown

A category is given a “P” when majority of the factors under that category has a positive impact. A category is given an “N” when majority of the factors under that category has a negative impact. A category is given “U” when majority of the factors, about 55 percent of the factors, are neither positive nor negative. In such cases, the factors with unknown impact will determine the overall impact of that category. Therefore, such categories were given an unknown impact.

Based on the analysis of the categories under Levels 1, 2 and 3 as well as the factors under each category, it can be inferred that Malaysia and Indonesia have a positive atmosphere for localization and it is recommended to localize in Malaysia and Indonesia provided that the internal factors in the company are also supportive. However, significant percentages of factors under Level 1, 2, and 3 have unknown impact on localization, and thus, it is important for Global Pharma to further explore the impact of unknown factors.

**Conclusions**

The decision framework application to Malaysia and Indonesia using external factors indicate that both countries have positive atmosphere to localize. As next steps, Global Pharma should perform the following:

1. Identify the factors with unknown impact.
2. Determine the impact of such factors either through market research or through surveys.

(3) Update the impact based on the results from above steps.

(4) Determine if the changes will impact the overall recommendation.

The limitations of this thesis are:

1. Only external factors are considered.
2. The study is purely qualitative.